Mar 7, 2021
[< 1 min Read]
Bellus Health (TSX:BLU)(NASDAQ:BLU) is a $397.17 million clinical-stage biopharmaceutical company from Laval, Canada. It develops therapeutics for the treatment of chronic cough, chronic pruritus, and other hypersensitization disorders. The company's lead drug candidate, BLU-5937, is now in phase two clinical trial.
Bellus Health President and CEO Roberto Bellini anticipate a transformative year ahead following the significant progress with the clinical development of BLU-5937 over the past 12 months. Management believes its lead drug candidate has the potential to treat a wide range of hypersensitization-related conditions.